Provided by Tiger Fintech (Singapore) Pte. Ltd.

SpringWorks Therapeutics, Inc.

46.96
+0.18000.38%
Post-market: 47.010.0500+0.11%18:15 EDT
Volume:11.12M
Turnover:522.32M
Market Cap:3.54B
PE:-13.76
High:47.02
Open:46.99
Low:46.95
Close:46.78
Loading ...
May 06, 2021

Major Issues Report

8-K - Current report
May 05, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 11, 2021

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Mar 04, 2021

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Feb 25, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Feb 25, 2021

Major Issues Report

8-K - Current report
Feb 25, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 25, 2021

Major Issues Report

8-K - Current report
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 11, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 08, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Dec 15, 2020

Major Issues Report

8-K - Current report
Nov 12, 2020

Major Issues Report

8-K - Current report
Nov 12, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 15, 2020

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Oct 14, 2020

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Oct 08, 2020

Major Issues Report

8-K - Current report
Aug 12, 2020

Major Issues Report

8-K - Current report
Aug 12, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]